Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.32 |
| ▸ | MC3R | P41968 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20011291 | 0.67 | GDA (0.31) | GDAALDH1A1TSHRCYP3A4PMP22 | |
| SCHEMBL31685444 | 0.63 | ALDH1A1 (0.38) | GDAPIK3CDPOLBADORA3CNR1 | |
| SCHEMBL20011085 | 0.60 | GDA (0.32) | GDAALDH1A1TSHRCYP3A4PMP22 | |
| SCHEMBL20151714 | 0.59 | — | — | |
| SCHEMBL18134852 | 0.58 | HTR1A (0.34) | — | |
| SCHEMBL14902045 | 0.58 | PNP (0.46) | GDAPIK3CDPOLBADORA3CNR1 | |
| SCHEMBL4407924 | 0.57 | ADRA2C (0.33) | — | |
| SCHEMBL6860825 | 0.57 | MEN1 (0.44) | BLM | |
| SCHEMBL24328585 | 0.55 | DRD4 (0.51) | — | |
| SCHEMBL4409585 | 0.53 | GSK3A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3924334-A1 | 3,6-DISUBSTITUTED-2-PYRIDINALDOXIME SCAFFOLDS | Centre national de la recherche scientifique (FR) | 2021-12-22 | — | — | EP | claimed |
| WO-2020165432-A1 | 3,6-DISUBSTITUTED-2-PYRIDINALDOXIME SCAFFOLDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-08-20 | — | — | WO | claimed |
| EP-3696170-A1 | 3,6-DISUBSTITUTED-2-PYRIDINALDOXIME SCAFFOLDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-08-19 | — | — | EP | claimed |
| US-20060211713-A1 | Compounds having selective hydrolytic potentials | CELL THERAPEUTICS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-0739203-A4 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS INC (US) | 2000-12-20 | — | — | EP | claimed |
| US-5985926-A | VIRICIDES OF AMINE COMPOUNDS AND HYDROCARBONS | CELL THERAPEUTICS, INC. (US) | 1999-11-16 | — | — | US | claimed |
| US-5889011-A | THERAPY FOR SEPSIS; ORGAN TOXICITY, ALOPECIA, ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES | CELL THERAPEUTICS, INC. (US) | 1999-03-30 | — | — | US | claimed |
| US-5807861-A | Amine substituted xanthinyl compounds | CELL THERAPEUTICS, INC. (US) | 1998-09-15 | — | — | US | claimed |
| US-5801181-A | Amino alcohol substituted cyclic compounds | CELL THERAPEUTICS, INC. (US) | 1998-09-01 | — | — | US | claimed |
| US-5756511-A | Method for treating symptoms of a neurodegenerative condition | CELL THERAPEUTICS, INC. (US) | 1998-05-26 | — | — | US | claimed |
| US-4883796-A | Oxime ethers of 2,6-dioxabicyclo(3.3.0)octanones, and compositions and methods for treatment of a cardiac disease or circulatory with them | HEINRICH MACK NACHF. (DE) | 1989-11-28 | — | — | US | claimed |
| EP-0171005-B1 | XANTHINYLMETHYLTHIAZOLIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) | 1989-11-23 | — | — | EP | claimed |
| EP-0198190-B1 | COMPOUNDS HAVING ANTIPLATELET AGGREGATION ACTIVITY, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELLEM INDUSTRIA FARMACEUTICA S.p.A. (IT) | 1989-05-31 | — | — | EP | claimed |
| EP-0284752-A1 | Oxime ethers of 2,6-dioxabicyclo[3.3.0]octanones | Heinrich Mack Nachf. (DE) | 1988-10-05 | — | — | EP | claimed |
| US-4737502-A | DIMETHYLXANTHINYL-SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENO(3,2-C)P PYRIDINES | ELLEM INDUSTRIA FARMACEUTICA S.P.A. (IT) | 1988-04-12 | — | — | US | claimed |
| EP-0199190-A2 | Separating element for separating solid particles, suspended in a gaseous current, by centrifugal force in a cylindrical whirl chamber | Anton Piller GmbH & Co. KG (DE) | 1986-10-29 | — | — | EP | claimed |
| EP-0198190-A2 | Compounds having antiplatelet aggregation activity, a process for the preparation thereof and pharmaceutical compositions containing them | ELLEM INDUSTRIA FARMACEUTICA S.p.A. (IT) | 1986-10-22 | — | — | EP | claimed |
| EP-0171005-A2 | Xanthinylmethylthiazolidines, process for their preparation and pharmaceutical compositions containing them | BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) | 1986-02-12 | — | — | EP | claimed |
| US-4535158-A | CHEMICXAL INTERMEDIATES FOR CARDIOTONIC AGENTS | DR. WILLMAR SCHWABE GMBH & CO. | 1985-08-13 | — | — | US | claimed |
| EP-0044932-B1 | OPTIONALLY N-SUBSTITUTED AMINO-DEOXY-1,4;3,6-DIANHYDRO-HEXITE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR APPLICATION | Dr. Willmar Schwabe GmbH & Co. (DE) | 1985-04-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211713-A1 | Compounds having selective hydrolytic potentials | CTSS, CTSE, GAA | GDA 299/4885PIK3CD 1622/4885POLB 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.